Guardian Pharmacy Services (GRDN) Stock Still Looks Cheap As It Rises 44% YTD

Guardian Pharmacy Services has climbed sharply so far this year, which puts fresh focus on a simple question for investors who care about cash flows. Are the cash streams that Guardian Pharmacy Services generates and expects to earn enough to justify where the stock now trades?

• Guardian Pharmacy Services is up 43.5% year to date, which raises the question of whether the share price has moved faster than its cash flow profile.
• Recent expansion through acquisitions and new locations may support expectations for higher future cash generation and could influence how far ahead the market is looking.
• Prefer to judge Guardian Pharmacy Services on earnings? See why Guardian Pharmacy Services's 35.9x P/E tells a different valuation story.

The issue now is whether the company's current share price is properly explained by the cash flows implied by a Discounted Cash Flow (DCF) intrinsic value estimate.

If you want a wider context for Guardian Pharmacy Services and its cash flow story, compare it with other companies using the solid balance sheet and fundamentals stocks screener (25 results).

Is Guardian Pharmacy Services Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here projects what Guardian Pharmacy Services' future cash streams might be worth in today's dollars. On the latest twelve month numbers the business generated roughly $95.1 million of free cash flow, with the DCF framework assuming that these cash flows keep growing rather than shrinking over the coming decade.

Those projections, when discounted back, put Guardian Pharmacy Services' estimated intrinsic value meaningfully above the current share price of $42.39. Because management recently raised full year guidance after stronger Q3 2026 results, the higher cash flow outlook helps explain why the DCF comes out ahead of where the stock trades today. Find out what Guardian Pharmacy Services could be worth using our Discounted Cash Flow (DCF) estimate.

The Guardian Pharmacy Services Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Guardian Pharmacy Services pick up where that DCF puzzle leaves off and explain which combinations of future growth, margins and earnings would need to occur for the stock to be worth materially more or materially less than today’s price. Instead of a single output from a ratio or model, Narratives break that figure into concrete forward assumptions that you can watch over time on Simply Wall St’s Community page.

One of the top narratives on Guardian Pharmacy Services: 14% undervalued

This Narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts' consensus price target and revenue and earnings forecasts, not one person's view.

"Active but disciplined M&A, supported by a debt free balance sheet, strong cash conversion above 60% and a flexible shelf registration, positions Guardian to accelerate regional density..."

Discover why this Narrative puts Guardian Pharmacy Services at 14% undervalued.

One more Guardian Pharmacy Services question that could change how you see it

Valuation models tell only part of the story, because the people steering Guardian Pharmacy Services and how they are rewarded can shape every future cash decision. See who runs Guardian Pharmacy Services and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com